Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 407-420-7 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Based on the 28 d subacute oral gavage study in rats, the NOAEL of the test substance was determined to be 1000 mg/kg bw/day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- May-July, 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study was conducted equivalent or similar to EU Method B.7. and OECD Guideline 407 in compliance with GLP
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River UK Limited, Manston Road, Margate, Kent, UK
- Age at study initiation: 6-7 wk
- Weight at study initiation: 147-167 g Males; 125-151 g females
- Housing: Housed individually in suspended cages (26.5cm x 50cm x 20.7cm)
- Diet (e.g. ad libitum): CT1 Diet, Special Diet Services Ltd, ad libitum
- Water (e.g. ad libitum): water, ad libitum
- Acclimation period: at least 6 d
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21±2 °C
- Humidity (%): 55±15 %
- Air changes (per hr): 25-30
- Photoperiod (hrs dark / hrs light): 12 h dark/12 h - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The preparations were made as suspensions in deionised water. For each dose level, an appropriate amount of water was added to a weighed amount of the undiluted test sample. Each preparation was thoroughly mixed and subdivided into aliquots. Further preparations were made at appropriate intervals throughout the study.
The doses used in the study were adjusted-for water content of the test substance(i.e., the daily dose levels administered were approximately equal
to 50, 200 and 1000 mg/kg body weight), but were not otherwise corrected for purity. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- A sample of each preparation was analysed prior to dosing to verify the achieved concentration of test substance in water. Trial dilutions of 5.6 and 11.7 mg/mL of the suspension were made prior to the study for the determination of chemical stability (over a 21-d period) and homogeneity of the test sample in deionised water.
- Duration of treatment / exposure:
- 28 d
- Frequency of treatment:
- Once a day for 28 d
- Remarks:
- Doses / Concentrations:
50, 200 and 1000 mg/kg bw/d
Basis:
other: Nominal in vehicle - No. of animals per sex per dose:
- 5/sex/dose in main groups
5/sex/dose in recovery groups
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based on the results obtained from a pilot oral study (CIL study number KR1130). In that study, groups of two male rats were given 14 consecutive daily doses of 250 or 1000 mg/kg/day. No signs of toxicity were seen in any of the animals and there were no macroscopic abnormalities at post mortem examination.
- Rationale for selecting satellite groups: To check the reversibility of the effects, if any
- Post-exposure recovery period in satellite groups: yes, 14 d - Positive control:
- Not used in the study
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily in all groups
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Daily throughout the study, immediately before dosing, when appropriate. In addition, all the animals were checked between 1 and 3 h after dosing
BODY WEIGHT: Yes
- Time schedule for examinations: weighed daily on days 1-29. Recovery group animals were additionally weighed on Day 36 and prior to termination on Day 43.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes, weekly
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At the termination of the study and after the recovery period (Day 29 or 43)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At the termination of the study and after the recovery period (Day 29 or 43)
URINALYSIS: Yes
- Time schedule for collection of urine: Few days before termination (Day 22-23) of the study as well as before (Day 37-38) the end of the recovery period
- Animals fasted: Yes, 16-18 h
OTHER: Bone marrow samples were taken and stored, but were not examined - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, all animals were necropsied and each animal was subjected to a macroscopic examination of major abdominal and thoracic viscera.
HISTOPATHOLOGY: Yes, Following tissues/organs were preserved in a suitable fixative and processed for histopathological investigations: adrenal gland, bone marrow (femur), brain, heart, colon, jejunum, kidneys, liver, lungs, lymph nodes (mandibular and iliac), ovaries, uterus, pituitary gland, thyroid and parathyroid glands, prostate gland, spleen, stomach, testis, epididymides, thymus, trachea, urinary bladder, Harderian gland and abnormal tissue. - Other examinations:
- No data
- Statistics:
- - ANCOVA for body weights
- ANOVA for food consumption, haematology, blood and urine clinical chemistry
- Organ weights were considered by ANOVA and ANCOVA on final bodyweight, separately for males and females
- All analyses were carried out using the GLM procedure in SAS
- Differences from control were tested statistically by comparing each treatment group LSM with the control group least square mean using a two-sided Student's t-test, based on the error mean square in the analysis - Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- effects observed, treatment-related
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY: No treatment related toxicity was observed in any group. All the animals dosed with the test substance had black faeces throughout most of the dosing phase of the study; this was not evident from Day 30 onwards in the animals retained until Day 43.
BODY WEIGHT AND WEIGHT GAIN: Statistically significantly lower body weights in males at 1000 mg/kg bw than the corresponding control group
FOOD CONSUMPTION: Males dosed with 1000 mg/kg killed on Day 29 was statistically significantly lower than their corresponding control group
HAEMATOLOGY: Slight decrease in haemoglobin on Day 29 in males and on Day 43 in both sexes dosed with 1000mg/kg,
CLINICAL CHEMISTRY: Increase in plasma total bilirubin in both sexes dosed with 1000 mg/kg. All the plasma samples from animals dosed with
1000 mg/kg and killed on Day 29 were coloured blue/grey or brown/grey.
URINALYSIS: Renal epithelial cells were present on Day 22-23 in the urine of females dosed with 1000mg/kg and killed on Day 29 and on Days 37-38 in both sexes dosed with 1000 mg/kg and killed on Day 43. At 1000 mg/kg, the urine samples were various shades of grey, brown, black or blue on Day 22-23, and light grey or grey on Day 37-38. As a consequence, none of the qualitative tests (ketones, glucose, urobilinogen and blood) could be done on Day 22-23 on the urine of animals dosed with 1000 mg/kg, the test strips being unreadable. Those at Day 37-38 were read normally.
ORGAN WEIGHTS: No significant change in organ weights
GROSS PATHOLOGY: Males and females dosed with 1000 mg/kg and killed on Day 29 or 43 showed blue discolouration of a wide range of organs. Similar, but reduced discolouration was present in rats dosed with 200 mg/kg, where it was confined to the stomach and kidney. Discolouration was not present in the animals dosed with 50 mg/kg.
HISTOPATHOLOGY: NON-NEOPLASTIC: Treatment-related findings were confined to the kidney and lung of females dosed at 1000 mg/kg. Minimal and subtle increase in neutral staining granularity of the cytoplasm of the proximal convoluted tubules. In the lung of two females there was a moderate pneumonitis characterised by thickening of the alveolar septae and mononuclear cell accumulation - Dose descriptor:
- NOAEL
- Effect level:
- 200 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: see 'Remark'
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: No significant biological effects were observed at any dose levels
- Critical effects observed:
- not specified
- Conclusions:
- Under the test conditions, the NOAEL is 1000 mg/kg body weight/day.
- Executive summary:
A study was conducted to assess the sub acute repeated dose toxicity of the test substance in rats equivalent or similar to EU Method B.7. and OECD guideline 407 in compliance with GLP
Groups of five male and five female rats were given 28 consecutive daily doses of 50, 200 or 1000 mg/kg of the test substance and were then subjected to a full post mortem examination. A similar group of animals was dosed with deionised water only and used as a control. Two further groups of five male and five female rats were dosed with either 1000 mg/kg of the test substance or deionised water and these animals were retained for 14 d without further treatment to allow a two week recovery period following the final dose of the test substance.
There were no clinical abnormalities of toxicological significance. The only clinical signs were black faeces during the dosing period and blue skin, both of which were due to colouration by the test substance.
Males dosed with 1000 mg/kg and killed on Day 29 had lower bodyweights and lower food consumption than the control group, but this was not evident when compared with the recovery control group and is considered to be unrelated to treatment.
There were no toxicologically significant effects on clinical chemistry, other than staining of the plasma and urine by the test substance. There were no toxicologically significant effects on haematology or organ weights.
The only pathological effects were in the kidneys and lungs of females dosed with 1000 mg/kg and killed on Day 29 and in the kidneys of females dosed with 1000mg/kg and killed on Day 43. In the kidney there was increased granularity in the proximal convoluted tubules which is considered to be due to, an accumulation of test substance within the kidney. Renal epithelial cells, seen in the urine of both groups of females dosed with 1000mg/kg and in the males killed on day 43, show that some exfoliation was occurring, but as there was no clear evidence of kidney damage this is considered not to be of toxicological significance. In the lung, two females showed pneumonitis. Leading to a NOAEL of 1000 mg/kg/day to male rats and 200 mg/kg/day to female rats. However, this NOAEL for female rats is only true for rats dosed by gavage. The test item administration at a high concentration and volume can lead to reflux of the administered formulation in the oesophagus and aspiration into the lung, leading to pneumonitis. This is not relevant for humans.
Hence, the NOAEL relevant for risk assessment is 1000 mg/kg body weight /day.
Reference
Results-Analysis of Dosing Preparations:
The concentrations of test substance in deionised water were within 11% of the nominal concentrations.
The homogeneity of test substance in deionised water was determined at 5.6 and 111.7 mg/mL and was shown to be satisfactory.
The chemical stability of test substance in deionised water was determined at 5.6 and 111.7mg/ml and was shown to be satisfactory over a 21-d period.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
A study was conducted to assess the sub acute repeated dose toxicity of the test substance in rats equivalent or similar to EU Method B.7. and OECD guideline 407 in compliance with GLP
Groups of five male and five female rats were given 28 consecutive daily doses of 50, 200 or 1000 mg/kg of the test substance and were then subjected to a full post mortem examination. A similar group of animals was dosed with deionised water only and used as a control. Two further groups of five male and five female rats were dosed with either 1000 mg/kg of the test substance or deionised water and these animals were retained for 14 d without further treatment to allow a two week recovery period following the final dose of the test substance.
There were no clinical abnormalities of toxicological significance. The only clinical signs were black faeces during the dosing period and blue skin, both of which were due to colouration by the test substance.
Males dosed with 1000 mg/kg and killed on Day 29 had lower bodyweights and lower food consumption than the control group, but this was not evident when compared with the recovery control group and is considered to be unrelated to treatment.
There were no toxicologically significant effects on clinical chemistry, other than staining of the plasma and urine by the test substance. There were no toxicologically significant effects on haematology or organ weights.
The only pathological effects were in the kidneys and lungs of females dosed with 1000 mg/kg and killed on Day 29 and in the kidneys of females dosed with 1000mg/kg and killed on Day 43. In the kidney there was increased granularity in the proximal convoluted tubules which is considered to be due to, an accumulation of test substance within the kidney. Renal epithelial cells, seen in the urine of both groups of females dosed with 1000 mg/kg and in the males killed on day 43, show that some exfoliation was occurring, but as there was no clear evidence of kidney damage this is considered not to be of toxicological significance. In the lung, two females showed pneumonitis, leading to a NOAEL of 1000 mg/kg/day to male rats and 200 mg/kg/day to female rats. However, this NOAEL for female rats is only true for rats dosed by gavage. The test item administration at a high concentration and volume can lead to reflux of the administered formulation in the oesophagus and aspiration into the lung, leading to pneumonitis. This is not relevant for humans.
Hence, the NOAEL relevant for risk assessment is 1000 mg/kg body weight /day (Parr-Dobrzanski R J & Leah AM, 1991).
Justification for classification or non-classification
Based on the 28 d oral gavage study in rats, the NOAEL of the test substance was determined to be 1000 mg/kg bw/day. Based on these results, the test substance does not meet the requirement for classification according to EC criteria (67/548/EEC) and according to CLP criteria (EC 1272/2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.